Monopar Therapeutics (MNPR) Competitors $46.82 -0.05 (-0.11%) Closing price 04:00 PM EasternExtended Trading$46.80 -0.02 (-0.05%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNPR vs. ELVN, GPCR, BGM, PRAX, ARDX, AVDL, SANA, DYN, AKBA, and COLLShould you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include Enliven Therapeutics (ELVN), Structure Therapeutics (GPCR), BGM Group (BGM), Praxis Precision Medicines (PRAX), Ardelyx (ARDX), Avadel Pharmaceuticals (AVDL), Sana Biotechnology (SANA), Dyne Therapeutics (DYN), Akebia Therapeutics (AKBA), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry. Monopar Therapeutics vs. Its Competitors Enliven Therapeutics Structure Therapeutics BGM Group Praxis Precision Medicines Ardelyx Avadel Pharmaceuticals Sana Biotechnology Dyne Therapeutics Akebia Therapeutics Collegium Pharmaceutical Enliven Therapeutics (NASDAQ:ELVN) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends. Do analysts prefer ELVN or MNPR? Enliven Therapeutics presently has a consensus target price of $41.20, indicating a potential upside of 87.70%. Monopar Therapeutics has a consensus target price of $60.00, indicating a potential upside of 28.15%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Enliven Therapeutics is more favorable than Monopar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Monopar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has better earnings & valuation, ELVN or MNPR? Monopar Therapeutics is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnliven TherapeuticsN/AN/A-$89.02M-$1.92-11.43Monopar TherapeuticsN/AN/A-$15.59M-$3.48-13.45 Is ELVN or MNPR more profitable? Enliven Therapeutics' return on equity of -31.84% beat Monopar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enliven TherapeuticsN/A -31.84% -30.09% Monopar Therapeutics N/A -55.39%-51.53% Do institutionals and insiders hold more shares of ELVN or MNPR? 95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 25.9% of Enliven Therapeutics shares are held by insiders. Comparatively, 20.5% of Monopar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, ELVN or MNPR? Enliven Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Does the media prefer ELVN or MNPR? In the previous week, Enliven Therapeutics had 3 more articles in the media than Monopar Therapeutics. MarketBeat recorded 8 mentions for Enliven Therapeutics and 5 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 1.44 beat Enliven Therapeutics' score of 0.40 indicating that Monopar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Monopar Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryEnliven Therapeutics beats Monopar Therapeutics on 9 of the 12 factors compared between the two stocks. Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNPR vs. The Competition Export to ExcelMetricMonopar TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$286.54M$3.06B$5.67B$9.50BDividend YieldN/A2.44%4.05%4.00%P/E Ratio-13.4520.9027.9219.98Price / SalesN/A245.97397.1882.73Price / CashN/A41.9636.1958.45Price / Book5.198.288.635.82Net Income-$15.59M-$55.19M$3.24B$258.42M7 Day Performance-0.91%5.09%3.17%1.94%1 Month Performance40.60%17.64%10.73%12.08%1 Year Performance1,363.13%7.03%35.04%20.90% Monopar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNPRMonopar Therapeutics2.7912 of 5 stars$46.82-0.1%$60.00+28.2%+1,364.7%$286.54MN/A-13.4510Positive NewsELVNEnliven Therapeutics2.7025 of 5 stars$21.87-3.5%$41.20+88.4%-9.1%$1.11BN/A-11.3950Insider TradeGPCRStructure Therapeutics3.0105 of 5 stars$18.13-5.8%$76.17+320.1%-49.5%$1.10BN/A-20.84136Positive NewsBGMBGM GroupN/A$10.63-5.8%N/AN/A$1.10B$25.10M0.00298News CoverageGap UpHigh Trading VolumePRAXPraxis Precision Medicines2.6076 of 5 stars$55.16+2.4%$94.11+70.6%-1.9%$1.10B$8.55M-5.15110ARDXArdelyx4.0054 of 5 stars$4.42+0.2%$10.89+146.4%-22.8%$1.06B$361.71M-20.0990AVDLAvadel Pharmaceuticals2.0489 of 5 stars$10.98+1.4%$18.33+67.0%-31.9%$1.05B$169.12M-40.6770SANASana Biotechnology3.2111 of 5 stars$4.44-4.1%$9.17+106.5%-18.3%$1.04BN/A-5.05380Gap UpDYNDyne Therapeutics3.7843 of 5 stars$9.17+1.7%$40.63+343.0%-78.7%$1.03BN/A-2.55100AKBAAkebia Therapeutics3.8352 of 5 stars$3.84-0.5%$6.75+75.8%+174.7%$1.01B$184.91M-18.28430Positive NewsCOLLCollegium Pharmaceutical4.4826 of 5 stars$30.91-0.9%$43.75+41.5%-3.6%$1.00B$631.45M25.34210News CoveragePositive News Related Companies and Tools Related Companies Enliven Therapeutics Alternatives Structure Therapeutics Alternatives BGM Group Alternatives Praxis Precision Medicines Alternatives Ardelyx Alternatives Avadel Pharmaceuticals Alternatives Sana Biotechnology Alternatives Dyne Therapeutics Alternatives Akebia Therapeutics Alternatives Collegium Pharmaceutical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNPR) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
